AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26605514 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF IVR
Number of subjects: 30
Study 26605514 — intervention group
Group type: COMPARATOR
Intervention: Placebo IVR
Number of subjects: 30
Study 25219639 — intervention group
Group type: EXPERIMENTAL
Intervention: COM.TEC
Number of subjects: 135
Study 25219639 — intervention group
Group type: EXPERIMENTAL
Intervention: Trima
Number of subjects: 135
Study 25219639 — intervention group
Group type: COMPARATOR
Intervention: All devices
Number of subjects: 135
Study 22910287 — intervention group
Group type: EXPERIMENTAL
Intervention: ID3 (3 μg HA per strain)
Number of subjects: 262
Study 22910287 — intervention group
Group type: EXPERIMENTAL
Intervention: ID9 (9 μg HA per strain)
Number of subjects: 262
Study 22910287 — intervention group
Group type: EXPERIMENTAL
Intervention: INT9 (9 μg HA per strain)
Number of subjects: 262
Study 22910287 — intervention group
Group type: COMPARATOR
Intervention: IM15 (15 μg HA per strain)
Number of subjects: 262
Study 20630124 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to media coverage or advertising about swine flu
Number of subjects: 1173
Study 20630124 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1173
Study 19638143 — intervention group
Group type: EXPERIMENTAL
Intervention: Active (bupivicaine 0.75%)
Number of subjects: 20
Study 19638143 — intervention group
Group type: COMPARATOR
Intervention: Sham (normal saline)
Number of subjects: 20
Study 16765453 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA)
Number of subjects: 25
Study 16765453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 15039849 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompressive craniectomy
Number of subjects: 5
Study 10640975 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant androgen deprivation therapy (ADT) for 3 months followed by radical prostatectomy (RP)
Number of subjects: 2
Study 10640975 — intervention group
Group type: COMPARATOR
Intervention: Radical prostatectomy (RP) alone
Number of subjects: 2
Study 10640975 — intervention group
Group type: EXPERIMENTAL
Intervention: PM2J004.5 anti-PSMA mAb
Number of subjects: 2
Study 10640975 — intervention group
Group type: EXPERIMENTAL
Intervention: 7E11 anti-PSMA mAb
Number of subjects: 2
Study 10640975 — intervention group
Group type: EXPERIMENTAL
Intervention: 7E11 and PM2J004.5 anti-PSMA mAbs
Number of subjects: 2
Study 9291380 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 unit (50 gram) of human polymerized hemoglobin (Poly SFH‐P)
Number of subjects: 39
Study 8303906 — intervention group
Group type: EXPERIMENTAL
Intervention: Population screening for cardiovascular risk factors (hypertension, smoking, physical inactivity)
Number of subjects: 2073
Study 8303906 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid values assessment
Number of subjects: 2073
Study 3330031 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (5-20 mg b.d.)
Number of subjects: 275
Study 3330031 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (subgroup of 11 patients)
Number of subjects: 275
Study 3330031 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (40-120 mg b.d.)
Number of subjects: 275
Study 3330031 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (subgroup of 11 patients)
Number of subjects: 275
Study 3330031 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 275
Study 3330031 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 275
Study 31365765 — intervention group
Group type: EXPERIMENTAL
Intervention: iGlarLixi (fixed-ratio combination of insulin glargine and lixisenatide)
Number of subjects: 0
Study 31365765 — intervention group
Group type: EXPERIMENTAL
Intervention: iGlarLixi
Number of subjects: 0
Study 31365765 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine alone
Number of subjects: 0
Study 31365765 — intervention group
Group type: COMPARATOR
Intervention: Lixisenatide alone
Number of subjects: 0
Study 29705484 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold therapy (ice packs for 20 minutes prior to chest tube removal)
Number of subjects: 180
Study 29705484 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (listening to music for 30 minutes starting 15 minutes prior to chest tube removal)
Number of subjects: 180
Study 29705484 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cold and music therapy
Number of subjects: 180
Study 29705484 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 180
Study 26747258 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupuncture (30 subjects)
Number of subjects: 57
Study 26747258 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (27 subjects)
Number of subjects: 57
Study 24930478 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Lifestyle Program (HeLP‐her Rural)
Number of subjects: 600
Study 24930478 — intervention group
Group type: COMPARATOR
Intervention: Control towns (n=21)
Number of subjects: 600
Study 22521235 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal irrigations with sulfurous‐arsenical‐ferruginous thermal water
Number of subjects: 70
Study 22521235 — intervention group
Group type: COMPARATOR
Intervention: Isotonic sodium chloride solution
Number of subjects: 70
Study 21189767 — intervention group
Group type: EXPERIMENTAL
Intervention: Gantrez‐NNP combination
Number of subjects: 2
Study 21189767 — intervention group
Group type: COMPARATOR
Intervention: Conventional toothpaste
Number of subjects: 2
Study 18729245 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg/day EFLA943 for 8 weeks
Number of subjects: 40
Study 18729245 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg/day EFLA943 for 8 weeks
Number of subjects: 40
Study 18729245 — intervention group
Group type: COMPARATOR
Intervention: Control group (lifestyle advice)
Number of subjects: 40
Study 18729245 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose group (500 mg/day EFLA943)
Number of subjects: 40
Study 18729245 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose group (1000 mg/day EFLA943)
Number of subjects: 40
Study 18729245 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 40
Study 15843668 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide
Number of subjects: 94
Study 15843668 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 94
Study 12027844 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium 0.2 mg/kg
Number of subjects: 20
Study 10340912 — intervention group
Group type: EXPERIMENTAL
Intervention: SB 209670 infusion at doses ranging from 0.2 to 1.5 microg kg(‐1) min(‐1) for approximately 8 hours
Number of subjects: 27
Study 10340912 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 27
Study 7582196 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 2 mg daily, starting 7 days before PTCA and continuing for 6 months
Number of subjects: 167
Study 7582196 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cilazapril)
Number of subjects: 167
Study 7582196 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril group
Number of subjects: 167
Study 7582196 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 167
Study 1819425 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone and sodium iodide diffusers
Number of subjects: 0
Study 1819425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7020181 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiography on days 5 to 11 after transplantation
Number of subjects: 25
Study 7020181 — intervention group
Group type: COMPARATOR
Intervention: Control group (no angiography)
Number of subjects: 25
Study 31054032 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based women's health survivorship care plan (SCP)
Number of subjects: 182
Study 31054032 — intervention group
Group type: COMPARATOR
Intervention: Attention control (curated resource lists)
Number of subjects: 182
Study 31054032 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based women's health SCP
Number of subjects: 182
Study 28523795 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health literacy intervention (5 sessions, 1.5 hours each over 1 year)
Number of subjects: 400
Study 28523795 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health literacy intervention
Number of subjects: 400
Study 28523795 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 400
Study 26505179 — intervention group
Group type: EXPERIMENTAL
Intervention: Aftercare over the telephone or face-to-face (up to 4 conversations over 3 months)
Number of subjects: 201
Study 26505179 — intervention group
Group type: EXPERIMENTAL
Intervention: Aftercare over the telephone or face-to-face
Number of subjects: 201
Study 26505179 — intervention group
Group type: COMPARATOR
Intervention: Aftercare over the telephone
Number of subjects: 201
Study 23859530 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissection after ligation (group 1)
Number of subjects: 114
Study 23859530 — intervention group
Group type: COMPARATOR
Intervention: Dissection before ligation (group 2)
Number of subjects: 114
Study 23859530 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 114
Study 22017192 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60/120 mg/day
Number of subjects: 524
Study 22017192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 524
Study 18665392 — intervention group
Group type: EXPERIMENTAL
Intervention: Task with two target-items in a stream of visual objects
Number of subjects: 0
Study 18665392 — intervention group
Group type: COMPARATOR
Intervention: Task with only a single target
Number of subjects: 0
Study 17335326 — intervention group
Group type: EXPERIMENTAL
Intervention: MLR methylphenidate
Number of subjects: 50
Study 17335326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 15211008 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic water filters
Number of subjects: 50
Study 15211008 — intervention group
Group type: COMPARATOR
Intervention: Customary water handling practices (Control)
Number of subjects: 50
Study 12053493 — intervention group
Group type: EXPERIMENTAL
Intervention: NIR stent with on-line visual IVUS criteria for optimization
Number of subjects: 70
Study 12053493 — intervention group
Group type: COMPARATOR
Intervention: Wallstent with on-line visual IVUS criteria for optimization
Number of subjects: 70
Study 9241623 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (10 mg daily)
Number of subjects: 107
Study 9241623 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (2.5‐5 mg daily)
Number of subjects: 107
Study 9241623 — intervention group
Group type: COMPARATOR
Intervention: Placebo for Simvastatin
Number of subjects: 107
Study 9241623 — intervention group
Group type: COMPARATOR
Intervention: Placebo for Enalapril
Number of subjects: 107
Study 8517105 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% ropivacaine
Number of subjects: 30
Study 8517105 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 30
Study 8517105 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 30
Study 8517105 — intervention group
Group type: EXPERIMENTAL
Intervention: All concentrations of ropivacaine
Number of subjects: 30
Study 8517105 — intervention group
Group type: EXPERIMENTAL
Intervention: AREMG method
Number of subjects: 30
Study 8517105 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory blockade
Number of subjects: 30
Study 8517105 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial motor block
Number of subjects: 30
Study 3430295 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg daily
Number of subjects: 29
Study 3430295 — intervention group
Group type: COMPARATOR
Intervention: Griseofulvin 1 g daily
Number of subjects: 29
Study 31665912 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of intrapancreatic autologous stem cell (ASC) infusion and hyperbaric oxygen treatment (HBOT)
Number of subjects: 23
Study 31665912 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 23
Study 27498549 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA‐S plasma levels in chronic neck pain group
Number of subjects: 12
Study 27498549 — intervention group
Group type: COMPARATOR
Intervention: DHEA‐S plasma levels in control group
Number of subjects: 12
Study 27498549 — intervention group
Group type: COMPARATOR
Intervention: DHEA‐S response after physical exercise in control group
Number of subjects: 12
Study 27498549 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA‐S response after physical exercise in chronic neck pain group
Number of subjects: 12
Study 26067559 — intervention group
Group type: EXPERIMENTAL
Intervention: External splint trimmed above the osteotomy lines (Group 2)
Number of subjects: 40
Study 26067559 — intervention group
Group type: COMPARATOR
Intervention: External splint extended beyond the osteotomy lines (Group 1)
Number of subjects: 40
Study 23375693 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-food elimination diet for 6 weeks
Number of subjects: 67
Study 20717048 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior lens capsule
Number of subjects: 0
Study 20717048 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin-C
Number of subjects: 0
Study 19615288 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide 200 mg orally daily + vinorelbine 25-30 mg/m² i.v. on D1 and D8 + cisplatin 70-80 mg/m² i.v. on D1
Number of subjects: 66
Study 19615288 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine 25-30 mg/m² i.v. on D1 and D8 + cisplatin 70-80 mg/m² i.v. on D1
Number of subjects: 66
Study 17414229 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (LD/MD: 20/5 mg, 30/7.5 mg, 40/10 mg, 60/15 mg)
Number of subjects: 43
Study 17414229 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel plus ASA (325 mg)
Number of subjects: 43
Study 17414229 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (300 mg LD/75 mg MD)
Number of subjects: 43
Study 17414229 — intervention group
Group type: COMPARATOR
Intervention: ASA alone
Number of subjects: 43
Study 14756599 — intervention group
Group type: EXPERIMENTAL
Intervention: Benefit finding
Number of subjects: 364
Study 11853116 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone treatment
Number of subjects: 15
Study 11853116 — intervention group
Group type: COMPARATOR
Intervention: Drug-free and drug-naive patients
Number of subjects: 15
Study 9855481 — intervention group
Group type: EXPERIMENTAL
Intervention: Good blenders (odorants selected to blend well in mixtures)
Number of subjects: 41
Study 9855481 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor blenders (odorants that blended poorly in mixtures)
Number of subjects: 41
Study 8005776 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitudes towards ex-mental patients' work behaviour
Number of subjects: 480
Study 8005776 — intervention group
Group type: EXPERIMENTAL
Intervention: Government provision for ex-mental patients
Number of subjects: 480
Study 8005776 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of welfare policies
Number of subjects: 480
Study 8005776 — intervention group
Group type: EXPERIMENTAL
Intervention: Social welfare policy
Number of subjects: 480
Study 2804589 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted low dose heparin prophylaxis
Number of subjects: 100
Study 2804589 — intervention group
Group type: COMPARATOR
Intervention: Fixed low dose heparin prophylaxis (calcium heparin 5000 units, 8‐hourly)
Number of subjects: 100
Study 5328359 — intervention group
Group type: EXPERIMENTAL
Intervention: Protryptiline (10 mg three times daily, max 60 mg daily)
Number of subjects: 20
Study 5328359 — intervention group
Group type: COMPARATOR
Intervention: Imipramine and Amitryptiline (control group)
Number of subjects: 20
Study 29704016 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise to strengthen the back muscles after surgery
Number of subjects: 152
Study 29704016 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 152
Study 29354915 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of acupoint catgut-embedding therapy and auricular point pressure
Number of subjects: 180
Study 29354915 — intervention group
Group type: COMPARATOR
Intervention: Auricular point pressure (control group)
Number of subjects: 180
Study 26151493 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus rhamnosus GG (LGG) 4.5 × 10(9) cfu/d for 4 weeks
Number of subjects: 30
Study 26151493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 26151493 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus rhamnosus GG (LGG)
Number of subjects: 30
Study 23322522 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of epirubicin and paclitaxel alone or with capecitabine (TEX)
Number of subjects: 287
Study 23322522 — intervention group
Group type: COMPARATOR
Intervention: New lesions or progression of non-target lesions
Number of subjects: 287
Study 21163722 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh diesel exhaust (DE)
Number of subjects: 38
Study 21163722 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh secondary organic aerosol (SOA)
Number of subjects: 38
Study 21163722 — intervention group
Group type: COMPARATOR
Intervention: Clean air (CA)
Number of subjects: 38
Study 19664904 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management program for COPD
Number of subjects: 0
Study 19664904 — intervention group
Group type: EXPERIMENTAL
Intervention: Oort approach
Number of subjects: 0
Study 19664904 — intervention group
Group type: COMPARATOR
Intervention: Schmitt procedure
Number of subjects: 0
Study 17185877 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitiglinide regimen (mitiglinide combined with once daily insulin glargine)
Number of subjects: 9
Study 17185877 — intervention group
Group type: COMPARATOR
Intervention: Intensive insulin regimen (multiple daily insulin regimen of aspart insulin and glargine)
Number of subjects: 9
Study 14678008 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5% human albumin solution (HAS)
Number of subjects: 15
Study 14678008 — intervention group
Group type: COMPARATOR
Intervention: Colloid (Gelofusine)
Number of subjects: 15
Study 11252546 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermatan sulfate
Number of subjects: 60000
Study 11252546 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 60000
Study 9562199 — intervention group
Group type: EXPERIMENTAL
Intervention: Adson's test (AT)
Number of subjects: 53
Study 9562199 — intervention group
Group type: EXPERIMENTAL
Intervention: Costoclavicular maneuver (CCM)
Number of subjects: 53
Study 9562199 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated arm stress test (EAST)
Number of subjects: 53
Study 9562199 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraclavicular pressure (SCP)
Number of subjects: 53
Study 7828256 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 112
Study 7828256 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal Tube (ETT)
Number of subjects: 112
Study 2519937 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg of 0.5% bupivacaine IP
Number of subjects: 15
Study 2519937 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 15
Study 1101457 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclandelate (200 mg four times daily for six weeks)
Number of subjects: 24
Study 1101457 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for six weeks)
Number of subjects: 24
Study 30987704 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (oral) for 2 months
Number of subjects: 20
Study 30987704 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 20
Study 28624096 — intervention group
Group type: EXPERIMENTAL
Intervention: Anacetrapib 100 mg
Number of subjects: 583
Study 28624096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 583
Study 26681704 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm (radio campaign)
Number of subjects: 5000
Study 26681704 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 5000
Study 23426718 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Number of subjects: 25
Study 16817274 — intervention group
Group type: EXPERIMENTAL
Intervention: Point application at Yishu, Pishu, Sanyinjiao, Zusanli, and interference therapy of controlling diet
Number of subjects: 64
Study 16817274 — intervention group
Group type: COMPARATOR
Intervention: Interference therapy of controlling diet
Number of subjects: 64
Study 12696562 — intervention group
Group type: EXPERIMENTAL
Intervention: High-folate diet (at least seven servings of vegetables, berries, and citrus fruit per day)
Number of subjects: 37
Study 12696562 — intervention group
Group type: COMPARATOR
Intervention: Low-folate diet (one serving of both vegetables and fruit per day)
Number of subjects: 37
Study 12696562 — intervention group
Group type: EXPERIMENTAL
Intervention: High-folate diet
Number of subjects: 37
Study 10360858 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 1.2 mg/kg
Number of subjects: 15
Study 10360858 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 1.8 mg/kg
Number of subjects: 15
Study 10360858 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 3 mg/kg
Number of subjects: 15
Study 7856824 — intervention group
Group type: EXPERIMENTAL
Intervention: P. falciparum antigen detection system (ParaSight F test)
Number of subjects: 0
Study 7856824 — intervention group
Group type: COMPARATOR
Intervention: Standard microscopic malaria diagnosis and quantitative buffy coat analysis
Number of subjects: 0
Study 1928672 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural fentanyl combined with 0.2% bupivacaine
Number of subjects: 25
Study 1928672 — intervention group
Group type: COMPARATOR
Intervention: Thoracic epidural fentanyl alone
Number of subjects: 25
Study 1928672 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 25
Study 7075649 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 15 mg twice daily
Number of subjects: 52
Study 7075649 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 30 mg retard once daily
Number of subjects: 52